医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

iPug Announces the Launch of iPug Research Suite™

2016年06月10日 AM07:24
このエントリーをはてなブックマークに追加


 

SAN FRANCISCO

iPug, the innovative digital health platform founded in Australia announces the launch of iPug Research Suite™ at the BIO International Convention 2016.

With iPug Research Suite™, iPug recruits and engages targeted participants for high quality and real-time research results. The iPug Research Suite has an intuitive web interface that allows researchers to develop questionnaires, quickly recruit and onboard research participants, export data for analysis as CSV files, or to SPSS and other statistical software systems. In addition, it can access the iPug web and app platform that uses its patent-pending technology to onboard and engage users in research as well as in educational behavior change programs and campaigns. This will allow faster recruitment of research participants, better engagement throughout the study, broader reach than traditional campaigns, and unprecedented data quality for impact evaluations and statistical analyses.

iPug is teaming up with Dr. Andrea C. Gielen, a professor at the Johns Hopkins Bloomberg School of Public Health and the director of the Johns Hopkins Center for Injury Prevention and Policy, and Ms. Eileen McDonald, associate scientist in the Center to roll out a new public health campaign in 2016 called D.O.S.E. (Digital-Opioid-Safety-Education) that will promote safe use, storage, and disposal of opioid pain medications to reduce the risk of addiction, diversion, overdose, and death.

At BIO, iPug will be at the Australian Pavilion from June 6-9th.

About iPug: iPug is the world’s first mobile friendly platform that transforms the way that research is conducted and how public health campaigns are delivered through mobile gamification.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160609006498/en/

CONTACT

iPug
Priya Ghandikota
press@ipug.co

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease